Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Rhea-AI Summary
Cogent Biosciences (Nasdaq: COGT) reported preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the 2026 EHA Congress. The candidate showed >100x selectivity over JAK2 wild-type and JAK1/3 isoforms, with high oral bioavailability, low clearance across species, and an IND filing planned in 2026.
Positive
- CGT1145 shows >100x selectivity over JAK2 wild-type and JAK1/3 isoforms
- Preclinical profile includes high oral bioavailability and low clearance across species
- Program targets prevalent JAK2 V617F mutation in multiple myeloproliferative neoplasms
- Investigational New Drug (IND) application for CGT1145 planned for 2026
Negative
- None.
News Market Reaction – COGT
In the Jun 12 session, COGT gained 1.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | NDA acceptance | Positive | +2.5% | FDA accepted Priority Review NDA for bezuclastinib plus sunitinib in GIST. |
| May 27 | Conference participation | Neutral | +1.7% | Jefferies conference participation and inducement equity grants to new employees. |
| May 12 | EHA data preview | Positive | +1.3% | Announcement of multiple EHA 2026 presentations including JAK2 V617F preclinical poster. |
| May 05 | Earnings update | Neutral | +0.7% | Q1 2026 results and update on NDAs, PDUFA date, cash runway into 2028. |
| Apr 21 | Phase 3 update | Positive | -0.7% | Positive Phase 3 PEAK trial data in GIST and upcoming ASCO oral presentation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially regulatory and clinical milestones, has usually been followed by modestly positive 1-day moves, with one notable divergence on a positive Phase 3 update.
Over the last few months, Cogent has reported multiple key milestones. Positive Phase 3 PEAK data in GIST and subsequent NDA submissions drew regulatory momentum, including FDA acceptance with Priority Review announced on May 28, 2026. The company also highlighted multiple presentations at the EHA 2026 Congress and provided Q1 2026 financials showing substantial cash of $866.4M to fund programs into 2028. Today’s JAK2 V617F preclinical data and 2026 IND timeline build on this pattern of advancing a multi-asset pipeline.
Key Terms
jak2 v617f medical
bcr-abl-negative medical
myeloproliferative neoplasms medical
polycythemia vera medical
essential thrombocythemia medical
oral bioavailability medical
investigational new drug regulatory
isoforms technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -
WALTHAM, Mass. and BOULDER, Colo., June 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential best-in-class JAK2 V617F mutant-selective inhibitor in a poster presentation at the 2026 European Hematology Association (EHA) Congress taking place in Stockholm, Sweden, June 11-14, 2026.
“We’re encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “This highly selective, potent inhibitor of JAK2 V617F has the potential to address the underlying mutational driver of disease while mitigating off-target hematological effects. We are rapidly advancing this program and remain on track to submit our Investigational New Drug application in 2026.”
JAK2 V617F is the most prevalent molecular abnormality in BCR-ABL-negative myeloproliferative neoplasms (MPNs), occurring in approximately
Cogent’s EHA posters and presentation will be available on the company’s website at: https://www.cogentbio.com/pipeline-publications/#posters-publications
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Ka, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the best-in-class potential of CGT1145, the company’s JAK2 V617F mutant-selective inhibitor candidate; the potential for CGT1145 to address the underlying mutational driver of disease while mitigating off-target hematological effects; the potential for CGT1145 to eradicate JAK2 V617F myeloproliferative neoplasm propagating cells and induce molecular remission with improved hematologic tolerability; and the company’s plan to submit an IND in 2026 for CGT1145. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Annual Report on Form 10-K, as supplemented by Quarterly Reports on Form 10-Q and other filings Cogent makes with the SEC from time to time . Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653